SCHEDULE: Vanguard Discloses 5.13% Stake in Accuray Inc

The Vanguard Group has reported a 5.13% beneficial ownership stake in Accuray Inc, holding 5,818,576 shares of common stock as of December 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 5,818,576 shares of Accuray Inc common stock.
• This represents 5.13% of Accuray Inc's outstanding common stock.
• The filing date for this disclosure was January 30, 2026, reflecting ownership as of December 31, 2025.
• Vanguard holds shared voting power over 803,553 shares and shared dispositive power over all 5,818,576 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Accuray Inc.
• An internal realignment at The Vanguard Group, effective January 12, 2026, means certain subsidiaries will report beneficial ownership separately going forward.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant passive investment by The Vanguard Group typically reflects inclusion in broad market or sector-specific index funds, indicating a stable, long-term institutional shareholder base for Accuray Inc.

Positives

• A significant institutional investor like The Vanguard Group holding a 5.13% stake can signal confidence in Accuray Inc's long-term prospects.
• The passive nature of Vanguard's investment, stated as being in the ordinary course of business and not for control, suggests a stable, long-term shareholder base.

Future Outlook

NA

Management Comments

• The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
• No one other person's interest in the securities reported herein is more than 5%.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that the disclosure of a significant passive stake by a major institutional investor like Vanguard in Accuray Inc, a company in the medical device and radiation oncology sector, typically reflects a long-term investment strategy. Such investments often indicate that the company aligns with broader market indices or specific sector funds managed by Vanguard, rather than a targeted strategic move to influence company operations. This passive accumulation of shares by large index fund managers is a common trend across various industries, reflecting the growth of passive investing.

Stakeholder Impact

• Shareholders: The presence of a large, stable institutional investor like Vanguard can provide a degree of stability to the share register and potentially enhance liquidity.
• Management: The passive nature of Vanguard's stake suggests no immediate pressure for strategic changes, allowing management to focus on long-term operational goals.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are anticipated to report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538, following an internal realignment effective January 12, 2026.

Key Dates

Recommendation

The filing indicates a significant passive stake by The Vanguard Group, which is generally a positive sign of institutional confidence and inclusion in major indices. However, as a Schedule 13G, it provides no operational or financial performance details for Accuray Inc. Therefore, while the institutional backing is favorable, a 'hold' recommendation is appropriate as further analysis of Accuray's fundamentals would be required for a stronger 'buy' or 'sell' decision.

Keywords

Accuray Inc, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment, medical devices, healthcare technology